Karl is co-founder of Aglaia BioMedical Ventures. He holds an MBA from the University of Georgia (USA), following his studies at The Netherlands School of Business, Nijenrode. Before starting up Aglaia, he was involved in the founding, restructuring and funding of multiple technology-driven companies. In 1995, he founded Entity Holding B.V., a venture company focusing on early-stage companies. Karl serves at the board of a number of life sciences companies.
Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017
Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer